Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    Error message

    • Deprecated function: Return type of DatabaseStatementBase::execute($args = [], $options = []) should either be compatible with PDOStatement::execute(?array $params = null): bool, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2246 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::current() should either be compatible with Iterator::current(): mixed, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::next() should either be compatible with Iterator::next(): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::key() should either be compatible with Iterator::key(): mixed, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::valid() should either be compatible with Iterator::valid(): bool, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::rewind() should either be compatible with Iterator::rewind(): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).

    Jim Kling

    News

    Greater fracture risk reduction seen with denosumab vs. zoledronic acid in postmenopausal women

    Author:
    Jim Kling
    Publish date: October 17, 2023

    The analysis took extra pains to remove bias through data that might be linked to potential confounders but could not reasonably be attributed to...

    • Read More

    News

    Biologics linked to fewer hospitalizations after asthma exacerbation

    Author:
    Jim Kling
    Publish date: October 11, 2023

    The study adds to growing data that biologics offer better long-term outcomes and could reduce health care utilization.

    • Read More

    News

    Short, long-lasting bronchodilators similar for exacerbated COPD

    Author:
    Jim Kling
    Publish date: October 10, 2023

    Long-lasting bronchodilators are recommended by the Gold Report, but clinical evidence was lacking in this population.

    • Read More

    News

    Nivolumab/Ipillimumab combo demonstrates long-term efficacy in NSCLC

    Author:
    Jim Kling
    Publish date: September 18, 2023

    “Most importantly, approximately 50% of these patients that are alive at six years are also disease free, suggesting that we are indeed making a...

    • Read More

    News

    Neoadjuvant durvalumab does not affect surgical outcomes in NSCLC: Study

    Author:
    Jim Kling
    Publish date: September 14, 2023

    AEGEAN is one of the first studies looking at immune checkpoint inhibitors in the perioperative settings that demonstrated improved EFS and pCR...

    • Read More

    News

    Surgery may worsen pleural mesothelioma survival outcomes

    Author:
    Jim Kling
    Publish date: September 13, 2023

    The first randomized, controlled trial shows greater mortality than chemotherapy alone, though surgical expertise may be a confounder.

    • Read More

    News

    ADCs show early promise in NSCLC

    Author:
    Jim Kling
    Publish date: September 12, 2023

    “ADCs are a new, rapidly evolving class of therapeutics, and I think that we will all have to be prepared for the future that is coming,” said Dr...

    • Read More

    News

    What is the proper treatment for posttraumatic headache? Expert debate

    Author:
    Jim Kling
    Publish date: July 5, 2023

    Preventative treatment could reduce chronification, but has the potential to worsen comorbidities.

    • Read More

    News

    Prodrome treatment with ubrogepant prevents migraines

    Author:
    Jim Kling
    Publish date: July 5, 2023

    Intervention also reduced prodromal symptoms in patients who could reliably predict oncoming headaches.

    • Read More

    News

    Migraine treatment with rimegepant linked to reduced barbiturate use

    Author:
    Jim Kling
    Publish date: June 30, 2023

    Real-world analysis suggests potential for improvements in medication overuse and dependency.

    • Read More

    News

    Migraine device expands treatment possibilities

    Author:
    Jim Kling
    Publish date: June 23, 2023

    New studies of remote electrical neuromodulation show efficacy in adolescents and safety during pregnancy.

    • Read More

    Article

    Cannabis RCT shows efficacy, AEs in migraine

    Author:
    Jim Kling
    Publish date: June 22, 2023

    First RCT in migraine suggests THC/CBD mix might be best, and that recreational doses may be higher than necessary.

    • Read More

    News

    Migraine clusters emerge from machine-learning analysis

    Author:
    Jim Kling
    Publish date: June 21, 2023

    Groupings somewhat reflect expert consensus, but also suggest therapeutic avenues.

    • Read More

    News

    New study backs up capecitabine dosing practice in metastatic BC

    Author:
    Jim Kling
    Publish date: June 14, 2023

    Study finds similar progression-free and overall survival in 7-day-on/7-day-off schedule, with fewer side effects than 14 days on, 7 days off.

    • Read More

    News

    In TNBC, repeated biopsies may reveal emergent HER2-low expression

    Author:
    Jim Kling
    Publish date: June 13, 2023

    Results could broaden eligibility for treatment with the antibody-drug conjugate trastuzumab deruxtecan.

    • Read More

    Pages

    • « first
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • …
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2023 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery